Research programme: mRNA based cancer vaccines - Moderna Therapeutics/Merck

Drug Profile

Research programme: mRNA based cancer vaccines - Moderna Therapeutics/Merck

Alternative Names: mRNA based personalised cancer vaccines - Moderna Therapeutics/Merck

Latest Information Update: 18 Oct 2016

Price : $50

At a glance

  • Originator Moderna Therapeutics
  • Developer Merck AG; Moderna Therapeutics
  • Class Cancer vaccines; RNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 13 Oct 2016 Moderna Therapeutics plans a phase I/II trial for Cancer in USA
  • 29 Jun 2016 Moderna Therapeutics and Merck collaborate for the development and commercialisation of mRNA based cancer vaccines in USA
  • 29 Jun 2016 Early research in Cancer (Combination therapy) in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top